Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus cisplatin as neoadjuvant therapy for resectable squamous NSCLC
ChiCTR1900024720Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel and cisplatin in Pulmonary squamous cell carcinoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Postoperative pathological complete response rate. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1900024720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024720.